
Agilent Technologies, Inc.
NYSE•A
CEO: Mr. Rodney Gonsalves
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1999-11-18
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
連絡先情報
時価総額
$35.67B
PER (TTM)
27.3
33.3
配当利回り
0.8%
52週高値
$160.27
52週安値
$96.43
52週レンジ
順位19Top 5.6%
6.2
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$1.86B+9.41%
直近4四半期の推移
EPS
$1.53+24.39%
直近4四半期の推移
フリーCF
$452.00M+16.50%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Total Revenue Increased 6% Nine months revenue reached $5.09B, up 6% compared to prior year; growth across all segments noted.
Life Sciences Segment Leads Growth Life Sciences segment revenue grew 14% for the quarter and 9% for nine months, driven by BIOVECTRA.
Operating Cash Flow Strong Net cash provided by operating activities totaled $1.01B for nine months, despite a decrease from 2024.
Stock Repurchases Continue Repurchased 2.734M shares for $340M during nine months ended July 31, 2025 under 2023 plan.
リスク要因
Net Income Declined 7% Nine months net income fell to $869M from $938M last year; diluted EPS decreased to $3.05.
Gross Margin Compression Noted Total gross margin decreased 2 percentage points to 52.2% for nine months due to tariffs and mix.
Tariff Impact on Costs Recent tariff changes adversely impacted cost of revenue in Q3; mitigation expected in fiscal year 2026.
Limited Market Visibility Quarterly results highly dependent on order timing, which is difficult to forecast; customer capital budgets constrained.
見通し
FY2025 Restructuring Completion FY25 Plan expected to substantially complete restructuring activities by second quarter fiscal year 2026.
Capital Spending Planned Expect total capital expenditures for the current year to be approximately $400M, focused on manufacturing expansion.
Focus on Differentiated Solutions Primary focus remains enhancing customer experience and delivering differentiated product solutions for long-term growth.
FY2025 Plan Cost Savings FY25 Plan expected to yield $75M to $80M in annual cost of sales and operating expense reduction.
同業比較
売上高 (TTM)
CAH$244.49B
TAK$30.01B
BDX$21.92B
粗利益率 (最新四半期)
78.1%
64.5%
RMD62.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| BDX | $63.72B | 28.5 | 6.4% | 32.8% |
| TAK | $58.32B | 78.5 | 1.6% | 31.5% |
| CAH | $51.96B | 31.3 | -58.9% | 15.5% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.4%
緩やかな成長
4四半期純利益CAGR
10.9%
収益性の着実な向上
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年2月25日
EPS:$1.37
|売上高:$1.81B
財務レポート
財務データ
全年度
Form 10-Q - Q3 2025
会計期末: 2025年7月31日|提出日: 2025年8月29日|売上高: $1.74B+10.1%|EPS: $1.18+21.6%予想を下回るForm 10-Q - Q2 2025
会計期末: 2025年4月30日|提出日: 2025年6月2日|売上高: $1.67B+6.0%|EPS: $0.75-28.6%予想を下回るForm 10-Q - Q1 2025
会計期末: 2025年1月31日|提出日: 2025年3月3日|売上高: $1.68B+1.4%|EPS: $1.12-5.9%予想を下回るForm 10-K - FY 2024
会計期末: 2024年10月31日|提出日: 2024年12月20日|売上高: $6.51B-4.7%|EPS: $4.44+5.2%予想を上回るForm 10-Q - Q3 2024
会計期末: 2024年7月31日|提出日: 2024年8月30日|売上高: $1.58B-5.6%|EPS: $0.97+155.3%予想を下回るForm 10-Q - Q2 2024
会計期末: 2024年4月30日|提出日: 2024年6月3日|売上高: $1.57B-8.4%|EPS: $1.05+2.9%予想を下回るForm 10-Q - Q1 2024
会計期末: 2024年1月31日|提出日: 2024年3月5日|売上高: $1.66B-5.6%|EPS: $1.19+0.0%予想通りForm 10-K - FY 2023
会計期末: 2023年10月31日|提出日: 2023年12月20日|売上高: $6.83B-0.2%|EPS: $4.22+0.7%予想を下回る